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Cutaneous B-cell lymphomas (CBCL) are a het-
erogeneous group of lymphoproliferative diseases1
that can be classified in 2 broad categories: primary
and secondary.2 The latter implies a systemic lym-
phoproliferative disease that causes visible cutaneous
lesions.2 Numerous articles regarding the diagnosis
and treatment of primary CBCL have been published.
However, there is a paucity of literature on local
therapeutic options for secondary CBCLs. Therefore,
we report a case of successful treatment of secondary
CBCL with intralesional rituximab.CASE REPORT
In August 2014, a 79-year-old man was sent to the
dermatology department for evaluation of erythem-
atous, infiltrated plaques on the scalp and fronto-
temporal regions evolving over a 6-month period.
His medical history included a squamous cell carci-
noma of the left scalp in 1990 treated by localized
excision, left cervical lymph node dissection, and
radiotherapy. In 2009, the patient presented to the
dermatology department with an erythematous
nodule on his forehead. Cutaneous biopsy found
follicle center cutaneous B-cell lymphoma with
immunohistochemistry profile positivity for CD20,
CD79, Bcl-2, and Bcl-6. He had positive translocation
(t[14:18]) on the cutaneous biopsy specimen. He
then underwent systemic workup. The computed
tomography scan found lymph nodes in the para-
vertebral area, around the aorta, and at the base of
the mesenteric vessels. His bone marrow biopsy
found the presence of lymphoma cells. Therefore,
systemic follicle center non-Hodgkin B-cell lym-
phoma was diagnosed and successfully treated
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remained clinically stable on follow-up with com-
plete regression of the cutaneous lesions until
August 2014 when the new cutaneous lesions were
reported. Cutaneous lesions resulting from his sys-
temic lymphoma was the primary working diag-
nosis. The patient was otherwise asymptomatic with
no general symptoms of fever, weight loss, or night
sweats. His positron emission tomography scan,
complete blood count, liver function tests, creati-
nine, and electrolytes were normal. He, therefore,
had a quiescent systemic disease and no indication
for chemotherapy.
On physical examination, there was an erythem-
atous infiltrated 4.2- 3 3-cm plaque on the left scalp
and 4 erythematous coalescent nodules on the left
and right frontotemporal regions. There were no
enlarged lymph nodes. We proceeded with a skin
biopsy of the largest plaque. Histopathology found a
dermal lymphocytic nodular infiltrate made of small
to intermediate size cells with notched nucleus
and the presence of dispersed large size cells.
Immunohistochemistry profile showed positivity
for CD79 and Bcl-2. A pathologist confirmed that
the cellular architecture was of follicle center origin.
Therefore, this information confirms the recurrence
of cutaneous lesions of the patient’s secondary
follicle center B-cell lymphoma even though his
systemic workup found no current active disease.
After literature review and discussion with the
patient and his hematologist-oncologist, we decidedJAAD Case Reports 2016;2:334-6.
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Fig 1. A and B, Cutaneous lesions before intralesional rituximab. C and D, The result after the
last treatment cycle.
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rituximab at a concentration of 10 mg/mL. Our
treatment regimen was based on the study for
intralesional rituximab in primary cutaneous B-cell
lymphomas by Gamo et al.1 We followed their
treatment protocol, and each cutaneous lesion was
injected with 10 to 30 mg (10 mg in the small nodules
and 30 mg in the large infiltrated plaque), 3 times a
week every 4 weeks until resolution. One treatment
cycle corresponds to 3 intralesional injections on
week 1 and 3 weeks without treatment. After the first
treatment cycle, all lesions had responded. Complete
regression of the right frontotemporal lesions was
noted after the first treatment cycle, the left fronto-
temporal lesions after the second, and the left scalp
after the third cycle (Fig 1). We recorded no
recurrence during treatment or during follow-up,
which is currently at 12months posttreatment. A total
cumulative dose of 185 mg of rituximab was used.
The treatment was well tolerated with only mild pain
of short duration at the injection sites. Complete
blood count, liver function tests, creatinine, and
electrolytes remained normal during treatment and
at follow-up.
DISCUSSION
Rituximab is a monoclonal antibody composed of
a murine anti-CD20 variable region and a human
IgG1 constant region. Rituximab binds to anti-CD20
antigens on malignant and benign B cells. Once
bound to anti-CD20 antigens, it signals for cell cycle
arrest and apoptosis.3 It is a well-documentedtherapeutic approach for primary cutaneous B-cell
lymphomas and systemic B-cell lymphomas. This
case report also shows its usefulness for local
treatment of secondary cutaneous follicle center B-
cell lymphoma with quiescent systemic disease.
The downfall with intralesional rituximab in sec-
ondary CBCL is the risk of relapse by not treating the
systemic disease. However, rituximab is found to
deplete peripheral circulating CD20 and CD19 B
lymphocytes for up to 6 months after intralesional
injection without causing side effects.3 We hypoth-
esize that this small systemic effect could possibly
have been sufficient to maintain an otherwise
inactive systemic disease, as we presented in this
article, while not causing disagreeable symptoms.
Advantages to intralesional rituximab are its
tolerability, with brief pain at injection sites,4 the
need for minimal amounts to achieve clinical
response compared with the doses needed in sys-
temic treatments, and the quick administration time.
It had no systemic effects on blood and chemistry
profile and was, therefore, well tolerated systemi-
cally. It also had no adverse effect on treated skin.We
noted no cutaneous atrophy and no scars.
Limitation to our treatment protocol could be the
lack of initial therapy with intralesional corticoste-
roids. This treatment option was initially considered
for our patient; however, the fact that rituximab is a
well-known useful treatment in primary cutaneous
B-cell lymphomas and has a tolerable side effect
profile, we chose to treat our patient with intrale-
sional rituximab before a trial of steroids.
JAAD CASE REPORTS
JULY 2016
336 Maillet-Lebel and ThibeaultCONCLUSION
Intralesional rituximab was a successful choice for
our patient. A gradual but complete response was
documented over the course of 3 months and 3
treatment cycles, without relapse during 12 months
of follow-up. This case shows the usefulness for local
treatment of secondary CBCL with otherwise quies-
cent systemic disease. It will be interesting to see how
long the remission period will last, for both skin
lesions and systemic disease. Although rituximabmay
not be a first-line therapeutic approach,we showed its
usefulness and effectiveness in this select case.REFERENCES
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